Abstract: The present disclosure is of a method for automated authoring of purposive models from Natural Language (NL) documents. Conventional model extractors to automatically extract models from NL documents are specific to a metamodel, do not consider document structure and are not configurable. Initially, the system receives a plurality of Natural Language (NL) documents, a metamodel, a plurality of pattern trees corresponding to the metamodel, and a configurable domain dictionary. Each of the plurality of pattern trees includes a plurality of pattern elements. Further, a document information is generated from each of the plurality of NL documents using a document information reading technique. Finally, a plurality of purposive models are generated for each of the plurality of NL documents by interpreting a corresponding document information based on the plurality of pattern trees and the metamodel using a pattern interpretation technique.

Abstract: The present disclosure extracts contextual product feature model from requirement specification documents where the conventional methods fail to perform. Initially, the system receives a plurality of requirement specification documents pertaining to a product, a domain dictionary, a plurality of configuration parameters, and a plurality of extraction patterns. A product feature model is generated using a NLP based feature extraction technique. The product feature model includes a plurality of product feature elements comprising a feature area, a major feature and a plurality of features arranged hierarchically and classified into feature types. Further, a plurality of ContextType associations like core, client, geography and market are extracted for each of the plurality of features using a ContextType extraction technique. Finally, the plurality of ContextType associations is updated in the product feature model to obtain a contextual product feature model.

Abstract: The present disclosure provides a holistic model for feature specification and dependency representation for requirement specification documents where the conventional models fail to provide. The present disclosure receives a plurality of requirement specification documents and a related data. A product feature model is generated based on the plurality of requirement specification documents and the related data using a feature model generation technique. The product feature model includes a plurality of product feature elements. The plurality of product feature elements includes a feature area, a major feature and a plurality of features. A specification model is generated further for each of the plurality of features using a specification extraction technique. Post generating the specification model, a plurality of dependency associations are generated for each of a plurality of specification elements of the specification model using a dependency extraction technique.

Abstract: The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.

Abstract: The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.

Abstract: The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.

Abstract: The invention is directed to biocompatible conjugated polymer nanoparticles including a copolymer backbone, a plurality of sidechains covalently linked to said backbone, and a plurality of platinum compounds dissociably linked to said backbone. The invention is also directed to dicarbonyl-lipid compounds wherein a platinum compound is dissociably linked to the dicarbonyl compound. The invention is also directed to methods of treating cancer or metastasis. The methods includes selecting a subject in need of treatment for cancer or metastasis and administering to the subject an effective amount of any of the nanoparticles, compounds, or compositions of the invention.

Abstract: The invention is directed to modified polymers with increased drug-loading including compounds of formula (I): wherein Z is a poly(lactic-co-glycolic acid) (PLGA) polymer having molecular weight from 1-15 kDa and where the ratio of lactide to glycolide in the PLGA polymer is from 1:10 to 10:1; formula (II) R1 are independently H, R2, OH, O-alkyl, —O—R2, NH—R2, -linker-R2, or -and R2 are independently one or more therapeutic agents. The invention is also directed to nanoparticle drug delivery systems including a PLGA-b-PEG block copolymer; and a stabilizer and to drug delivery systems including PLGA-b-PEG block copolymer polyvinyl alcohol (PVA) nanoparticle; and the modified polymer substantially as described herein.